Abstract
In the present study we used the model of cultured somatostatin-receptor-positive prolactin (PRL)-secreting rat pituitary tumor cells to investigate the possible interrelationships between the anti-mitotic and hormone-release-inhibitory effects of the somatostatin analog octreotide (SMS 201-955) and the effects of vincristine, methotrexate, fluouracil and suramin. Dose-dependent inhibitory effects of all compounds were shown both on the DNA content and on PRL release. Octreotide and these cytostatic compounds were slightly additive in their anti-proliferative and anti-secretory effects. The somatostatin analog did not alter drug sensitivity in these tumor cells, however. The data obtained in this tumor model suggest that octreotide can be effectively administered in combination with cytostatic drugs and/or suramin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
